Navigation Links
Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
Date:1/17/2013

NATICK, Mass., Jan. 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended December 31st, 2012 on Tuesday, January 29th, at 8:00 a.m. ET.

The call will be hosted by Michael Mahoney , president and chief executive officer, and Jeff Capello , executive vice president and chief financial officer.

A live webcast of the conference call will be available via Boston Scientific's website.  Webcast registration is available on the Investor Relations section of the website at www.bostonscientific.com/investors.  Interested parties are encouraged to register at least 15 minutes prior to the scheduled start time to ensure a timely connection.

The webcast is also being distributed over Thomson Reuters Investor Distribution Network via two locations: www.earnings.com, which is accessible to the public, and www.streetevents.com, a password-protected event management site.

An archived replay of the webcast will be accessible at www.bostonscientific.com/investors approximately one hour following the completion of the conference call and available for approximately one year.

The company will issue a press release announcing financial results for the fourth quarter and full year 2012 on Tuesday, January 29th, prior to the conference call.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit us at www.bostonscientific.com.

CONTACT:  

Steven Campanini
508-652-5740 (office)
Media Relations
Boston Scientific Corporation
media@bsci.com

Michael Campbell
508-650-8023 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
2. Boston Childrens Hospital announces international genomics competition winner
3. BioBDx to Present at the 2012 BioPharm America and AdvaMed MedTech Conferences in Boston
4. Alacrita Establishes U.S. Headquarters in Boston Area
5. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
6. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
7. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
8. Source Scientific LLC is 100% Acquired by BIT Analytical Instruments
9. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
10. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
11. Provia Labs’ Store-A-Tooth™ Announces Top Expert in Stem Cell Biobanking as its Scientific Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):